STOCK TITAN

Bioventus Inc. - $BVS STOCK NEWS

Welcome to our dedicated page for Bioventus news (Ticker: $BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bioventus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bioventus's position in the market.

Rhea-AI Summary
Bioventus CEO to participate in fireside chat at Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.22%
Tags
conferences
-
Rhea-AI Summary
Bioventus Inc. reports Q2 net sales of $137.1 million, down 2.3% YoY. Adjusted EBITDA increases 26.1% to $28.2 million. Loss per share of Class A common stock decreases to $0.06. Non-GAAP earnings per share of Class A common stock increase to $0.14. Total net sales decline due to lower Pain Treatment pricing and Wound Business divestiture. Gross margin decreases to 65.0%. Operating income improves to $6.8 million. Net loss from continuing operations decreases to $4.7 million. Adjusted EBITDA increases to $28.2 million. Non-GAAP net income and earnings per share of Class A common stock increase to $10.9 million and $0.14, respectively. Company expects net sales of $490 million to $505 million for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.12%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.27%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.17%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.48%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.96%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
conferences earnings
Bioventus Inc.

Nasdaq:BVS

BVS Rankings

BVS Stock Data

253.40M
23.20M
11.14%
66.3%
0.99%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
DURHAM

About BVS

bioventus® is a global leader in orthobiologics and its mission is to make a difference by helping patients resume and enjoy active lives. bioventus accomplishes this with its orthobiologic products for musculoskeletal healing, regeneration and related biosurgery that engage and enhance the body’s natural healing processes. the company has two product portfolios for orthobiologics, bioventus active healing therapies and bioventus surgical, which are created through a combination of internal product development, product/business acquisition, and distribution agreements. established in 2012, bioventus is privately held and headquartered in durham, nc. the company has nearly 600 employees worldwide and its international headquarters is in hoofddorp, the netherlands. bioventus also has offices in memphis, tn, australia and canada, and a research and development site is located in boston. bioventus works with patients, payers and health care providers throughout the world, and generat